首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1402602

正腎上腺素抑制劑市場：依應用、分銷管道和地區分類

Serotonin Norepinephrine Inhibitor Market, By Application, By Distribution Channel, By Region

出版日期: 2023年12月20日 | 出版商:

Coherent Market Insights | 英文 130 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2023年全球正腎上腺素抑制劑市場規模將達62.9億美元，2023年至2030年複合年成長率為4.2%。到2030年，市場規模預計將達到84.1億美元。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	62.9億美元
實際資料	2018-2021	預測期	2023-2030
預測期複合年成長率	4.20%	2030年市場規模預測	84.1億美元

圖 1. 2023 年依地區分類的正腎上腺素抑制劑的全球市場佔有率(%)

正腎上腺素再回收抑制劑(SNRI) 是一類常用作治療重度憂鬱症(MDD) 和其他情緒障礙的抗憂鬱症藥物的藥物。 SNRIs 透過抑制血清素和去甲腎上腺素（大腦中兩種重要的神經傳導物質）的再攝取來發揮作用。透過抑制這些神經傳導物質再攝取（再攝取）到神經元中，SNRI 可以增加大腦中血清素和正腎上腺素的濃度並增強其作用。血清素與情緒、情緒和睡眠有關。去甲腎上腺素與警覺性和精力有關。增加這些神經傳導物質的數量可以改善腦細胞之間的溝通，對情緒產生積極影響，並且對患有憂鬱症的患者有益。

常用的 SNRI 處方包括：

文拉法辛（Effexor XR）
Duloxetine（Cymbalta）
Desvenlafaxine（Pristiq）
levomilnacipran（Fetzima）

SNRI 也被核准用於治療焦慮症、纖維肌痛等慢性疼痛以及與糖尿病相關的神經病變疼痛。

市場動態：

全球憂鬱症患者數量的增加是推動全球正腎上腺素抑制劑市場成長的主要因素。據世界衛生組織（WHO）稱，全球超過5.0%的人口患有憂鬱症。由於導致憂鬱症發展的各種因素，例如增加的社會隔離和壓力大的職場環境，預計這個數字在不久的將來還會增加。對有效治療憂鬱症的需求不斷成長也推動了該市場的成長。 COVID-19 大流行的出現導致一些國家的失業率上升，並導致金融不穩定。結果，家庭收入減少，造成民眾壓力和焦慮，增加了抗憂鬱症的需求。

另一方面，藥物相關副作用預計將阻礙全球正腎上腺素抑制劑市場的成長。

本研究的主要特點

該報告詳細分析了全球正腎上腺素抑制劑市場，並提供了以2022年為基準年的預測期（2023-2030）的市場規模和年複合成長率（CAGR%）。
本報告還揭示了各個區隔市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
本報告還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
根據公司亮點、產品系列、主要亮點、業績和策略等參數對全球正腎上腺素抑制劑市場的主要參與者進行了分析。
該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
全球正腎上腺素抑制劑市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
相關人員可以透過用於分析全球正腎上腺素抑制劑市場的各種策略矩陣來促進他們的決策。

公司簡介
- Pfizer Inc.
- Eli Lilly and Company
- Allergan Plc.
- AstraZeneca Plc.
- Forest Laboratories Inc.
- Johnson &Johnson
- Lundbeck A/S
- Merck &Co., Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
- Wyeth Pharmaceuticals Inc.
- Zydus Cadila Healthcare Ltd.
分析師觀點

第9章章節

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI5718

Global serotonin norepinephrine inhibitor market was valued at USD 6.29 bn in 2023 and is expected to exhibit a compounded annual growth rate (CAGR) of 4.2% from 2023 to 2030. By 2030, the market is estimated to reach USD 8.41 bn.

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 6.29 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	4.20%	2030 Value Projection:	US$ 8.41 Bn

Figure 1. Global Serotonin Norepinephrine Inhibitor Market Share (%), By Region, 2023

Serotonin Norepinephrine Inhibitor Market - IMG1

A Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) is a class of medications typically used as antidepressants in the treatment of major depressive disorder (MDD) and other mood disorders. SNRIs work by inhibiting the reuptake of two important neurotransmitters in the brain - serotonin and norepinephrine. By blocking the reabsorption (reuptake) of these neurotransmitters into the neurons, SNRIs increase the levels and enhance the actions of serotonin and norepinephrine in the brain. Serotonin is involved in mood, emotion, and sleep. Norepinephrine is related to alertness and energy. Increasing the amount of these neurotransmitters improves communication between the brain cells and can have a positive impact on mood and emotion, which is beneficial for patients suffering from depression.

Some commonly prescribed SNRIs include:-

Venlafaxine (Effexor XR)
Duloxetine (Cymbalta)
Desvenlafaxine (Pristiq)
Levomilnacipran (Fetzima)

SNRIs are also approved to treat other conditions such as anxiety disorders, chronic pain conditions like fibromyalgia, and neuropathic pain associated with diabetes.

Market Dynamics:

Rising number of people suffering from depression globally is a major factor driving the market growth of the global serotonin norepinephrine inhibitor market. According to World Health Organization (WHO), over 5.0% of the worldwide population suffers from depression. This number is expected to increase in the near future, due to various factors such as increasing social isolation and stressful work environment, which leads to the development of depression. The increase in the demand for effective treatment of depression is also driving the growth of this market. The emergence of COVID-19 pandemic increased the unemployment rate in several countries and has led to financial instability. This has resulted in a decrease in the household income, which is causing stress and anxiety among people which in turn is increasing the demand for antidepressant drugs.

On the other hand, side effects associated with the drugs is expected to hamper the market growth of the global serotonin norepinephrine inhibitor market.

Key features of the study:

This report provides in-depth analysis of the global serotonin norepinephrine inhibitor market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global serotonin norepinephrine inhibitor market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer Inc., Eli Lilly and Company, Allergan Plc., AstraZeneca Plc., Forest Laboratories Inc., Johnson & Johnson, Lundbeck A/S, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Wyeth Pharmaceuticals Inc., and Zydus Cadila Healthcare Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global serotonin norepinephrine inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global serotonin norepinephrine inhibitor market

Detailed Segmentation:

Global Serotonin Norepinephrine Inhibitor Market, By Application
- Depression
- Anxiety Disorders
- Chronic Pain
- Diabetic Neuropathy
- Others
Global Serotonin Norepinephrine Inhibitor Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Serotonin Norepinephrine Inhibitor Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Top Companies in the Global Serotonin Norepinephrine Inhibitor Market
- Pfizer Inc.
- Eli Lilly and Company
- Allergan Plc.
- AstraZeneca Plc.
- Forest Laboratories Inc.
- Johnson & Johnson
- Lundbeck A/S
- Merck & Co., Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
- Wyeth Pharmaceuticals Inc.
- Zydus Cadila Healthcare Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
Increase prevalence of depression and anxiety disorders
Availability of new and improved drugs
- Restraints
Side effects
- Opportunities
Increasing adoption of telemedicine
Key Highlights
Regulatory Scenario
Recent trends
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Mergers, Acquisitions and Collaborations

4. Global Serotonin Norepinephrine Inhibitor Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Serotonin Norepinephrine Inhibitor Market, By Application, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Depression
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Anxiety Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Chronic Pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Diabetic Neuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

6. Global Serotonin Norepinephrine Inhibitor Market, By Distribution Channel, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

7. Global Serotonin Norepinephrine Inhibitor Market, By Region, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, For Sub-region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Sub-region, 2019 - 2030
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
U.K.
Germany
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
China
Japan
India
Australia
South Korea
ASEAN
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2018-2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Bn)
North Africa
Central Africa
South Africa